CN110099697B - 用于消融造血干细胞的抗体药物缀合物 - Google Patents

用于消融造血干细胞的抗体药物缀合物 Download PDF

Info

Publication number
CN110099697B
CN110099697B CN201780079504.9A CN201780079504A CN110099697B CN 110099697 B CN110099697 B CN 110099697B CN 201780079504 A CN201780079504 A CN 201780079504A CN 110099697 B CN110099697 B CN 110099697B
Authority
CN
China
Prior art keywords
seq
fab
light chain
antibody
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780079504.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110099697A (zh
Inventor
B·温
A·E·博伊塔诺
M·比尔热
S·E·塞利蒂
M·P·库克
C·芬纳
B·H·盖尔斯坦格尔
陈允豪
S·T·李-赫夫利希
H·T·彭
S·H·施莱尔
K·蒂索
宇野哲郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202311642832.9A priority Critical patent/CN117653740A/zh
Publication of CN110099697A publication Critical patent/CN110099697A/zh
Application granted granted Critical
Publication of CN110099697B publication Critical patent/CN110099697B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780079504.9A 2016-12-21 2017-12-19 用于消融造血干细胞的抗体药物缀合物 Active CN110099697B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311642832.9A CN117653740A (zh) 2016-12-21 2017-12-19 用于消融造血干细胞的抗体药物缀合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662437622P 2016-12-21 2016-12-21
US62/437,622 2016-12-21
US201762520854P 2017-06-16 2017-06-16
US62/520,854 2017-06-16
PCT/IB2017/058159 WO2018116178A1 (en) 2016-12-21 2017-12-19 Antibody drug conjugates for ablating hematopoietic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311642832.9A Division CN117653740A (zh) 2016-12-21 2017-12-19 用于消融造血干细胞的抗体药物缀合物

Publications (2)

Publication Number Publication Date
CN110099697A CN110099697A (zh) 2019-08-06
CN110099697B true CN110099697B (zh) 2023-11-28

Family

ID=60957364

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780079504.9A Active CN110099697B (zh) 2016-12-21 2017-12-19 用于消融造血干细胞的抗体药物缀合物
CN202311642832.9A Pending CN117653740A (zh) 2016-12-21 2017-12-19 用于消融造血干细胞的抗体药物缀合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311642832.9A Pending CN117653740A (zh) 2016-12-21 2017-12-19 用于消融造血干细胞的抗体药物缀合物

Country Status (23)

Country Link
US (2) US11357864B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP3558389A1 (US20040106767A1-20040603-C00005.png)
JP (2) JP7181203B2 (US20040106767A1-20040603-C00005.png)
KR (2) KR20190099238A (US20040106767A1-20040603-C00005.png)
CN (2) CN110099697B (US20040106767A1-20040603-C00005.png)
AU (1) AU2017383458C1 (US20040106767A1-20040603-C00005.png)
BR (1) BR112019012483A2 (US20040106767A1-20040603-C00005.png)
CA (1) CA3045592A1 (US20040106767A1-20040603-C00005.png)
CL (1) CL2019001745A1 (US20040106767A1-20040603-C00005.png)
CO (1) CO2019006455A2 (US20040106767A1-20040603-C00005.png)
CR (1) CR20190296A (US20040106767A1-20040603-C00005.png)
CU (1) CU24644B1 (US20040106767A1-20040603-C00005.png)
EA (1) EA201991526A1 (US20040106767A1-20040603-C00005.png)
EC (1) ECSP19044625A (US20040106767A1-20040603-C00005.png)
IL (2) IL300567A (US20040106767A1-20040603-C00005.png)
JO (1) JOP20190155A1 (US20040106767A1-20040603-C00005.png)
MA (1) MA47231A (US20040106767A1-20040603-C00005.png)
MX (1) MX2019007582A (US20040106767A1-20040603-C00005.png)
MY (1) MY193985A (US20040106767A1-20040603-C00005.png)
PE (1) PE20191539A1 (US20040106767A1-20040603-C00005.png)
PH (1) PH12019501330A1 (US20040106767A1-20040603-C00005.png)
TW (2) TWI778994B (US20040106767A1-20040603-C00005.png)
WO (1) WO2018116178A1 (US20040106767A1-20040603-C00005.png)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3452492A1 (en) * 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
SG11201811290VA (en) * 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
UY38265A (es) * 2018-06-20 2020-01-31 Novartis Ag Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN112739339A (zh) * 2018-07-23 2021-04-30 美真达治疗公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
MX2021004231A (es) * 2018-10-23 2021-06-15 Magenta Therapeutics Inc Conjugados de anticuerpos y fármacos (caf) con silenciamiento de fc y usos de los mismos.
EP3873532A1 (en) * 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
EP3817773A4 (en) * 2018-11-26 2021-09-15 Forty Seven, Inc. HUMANIZED ANTIBODIES AGAINST C-KIT
EP3894387A4 (en) * 2018-12-12 2023-07-19 Levim Biotech LLP ACYLATION PROCESSES FOR THE PRODUCTION OF N-SUBSTITUTED PEPTIDES
JP2022535527A (ja) * 2019-06-04 2022-08-09 マジェンタ セラピューティクス インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
CN112569368A (zh) 2019-08-07 2021-03-30 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物及其应用
CN116183899B (zh) * 2023-04-28 2023-06-30 天津市协和医药科技集团有限公司 一种吖啶酯标记抗体保存液的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138615A2 (en) * 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
CN105007950A (zh) * 2013-03-15 2015-10-28 诺华股份有限公司 抗体药物缀合物
WO2016020791A1 (en) * 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ATE287257T1 (de) 1997-01-16 2005-02-15 Massachusetts Inst Technology Zubereitung von partikelhaltigen arzneimitteln zur inhalation
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
US7151164B2 (en) 2002-02-14 2006-12-19 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
KR20110091598A (ko) 2003-03-24 2011-08-11 지모제넥틱스, 인코포레이티드 항-ｉｌ-22ｒａ 항체 및 결합 파트너 및 염증에 있어서의 사용 방법
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
ES2642205T3 (es) 2006-11-03 2017-11-15 The Board Of Trustees Of The Leland Stanford Junior University Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
MX2015010146A (es) 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
CA2951368A1 (en) 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
EP3215519A1 (en) * 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
CA2982115A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
EP3310813A1 (en) * 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
SG11201811290VA (en) * 2016-06-17 2019-01-30 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105007950A (zh) * 2013-03-15 2015-10-28 诺华股份有限公司 抗体药物缀合物
WO2015138615A2 (en) * 2014-03-12 2015-09-17 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
WO2016020791A1 (en) * 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates

Also Published As

Publication number Publication date
IL267478B1 (en) 2023-03-01
US11357864B2 (en) 2022-06-14
CN117653740A (zh) 2024-03-08
MA47231A (fr) 2019-10-30
JOP20190155A1 (ar) 2019-06-23
TW202300524A (zh) 2023-01-01
PH12019501330A1 (en) 2020-03-02
RU2019122794A (ru) 2021-01-22
CU24644B1 (es) 2023-02-13
AU2017383458A1 (en) 2019-06-13
ECSP19044625A (es) 2019-06-30
CO2019006455A2 (es) 2019-06-28
IL300567A (en) 2023-04-01
KR20240093751A (ko) 2024-06-24
EP3558389A1 (en) 2019-10-30
BR112019012483A2 (pt) 2020-04-14
IL267478B2 (en) 2023-07-01
US20190321483A1 (en) 2019-10-24
MX2019007582A (es) 2019-09-06
JP2023015080A (ja) 2023-01-31
CU20190061A7 (es) 2020-03-04
US20220305134A1 (en) 2022-09-29
EA201991526A1 (ru) 2020-01-24
AU2017383458B2 (en) 2021-04-29
MY193985A (en) 2022-11-04
CL2019001745A1 (es) 2019-09-13
TW201828991A (zh) 2018-08-16
CA3045592A1 (en) 2018-06-28
TWI778994B (zh) 2022-10-01
PE20191539A1 (es) 2019-10-23
JP7181203B2 (ja) 2022-11-30
CR20190296A (es) 2019-09-13
WO2018116178A1 (en) 2018-06-28
JP2020504112A (ja) 2020-02-06
AU2017383458C1 (en) 2021-08-12
RU2019122794A3 (US20040106767A1-20040603-C00005.png) 2021-10-12
KR20190099238A (ko) 2019-08-26
IL267478A (en) 2019-08-29
CN110099697A (zh) 2019-08-06

Similar Documents

Publication Publication Date Title
CN110099697B (zh) 用于消融造血干细胞的抗体药物缀合物
JP2019047807A (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
JP2021166538A (ja) ブラジキニンｂ１受容体リガンドに対する抗体
JP2021523874A (ja) 抗メソセリン抗体およびその抗体薬物コンジュゲート
CN113316591A (zh) Cd73抗体及其制备方法和应用
EP3795591A1 (en) Cys80 conjugated immunoglobulins
RU2723940C2 (ru) Биспецифические антигенсвязывающие полипептиды
US20210228731A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
JP6936399B2 (ja) 抗ｓｅｚ６抗体薬物コンジュゲート及び使用方法
RU2781444C2 (ru) Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток
US11999786B2 (en) Anti-CD48 antibodies, antibody drug conjugates, and uses thereof
EA044279B1 (ru) Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток
NZ794433A (en) Antibody drug conjugates for ablating hematopoietic stem cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant